Rosana Kapeller is an Entrepreneur in Residence at GV, focused on the intersection of therapeutics and machine learning. She brings over 25 years of scientific leadership and entrepreneurial experience to her role.
Rosana was the founding Chief Scientific Officer of Nimbus Therapeutics, where she led the company’s initiative to apply advanced computational technologies to the design and development of novel therapeutics. Rosana’s vision and leadership was instrumental in the discovery of the ACC inhibitor for NASH, acquired by Gilead. Previously, Rosana served as co-founder and VP of Research at Aileron Therapeutics. Early in her career, she spent 10 years at Millennium Pharmaceuticals, and also spent time as a consultant for Third Rock Ventures and Atlas Venture.
Rosana earned her M.D. from Universidade do Estado do Rio de Janeiro in Brazil and her Ph.D. in Molecular and Cellular Biology from Tufts University.